Skip to main content
Journal cover image

Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.

Publication ,  Journal Article
Mital, R; Otto, TS; Savu, A; Baumrin, E; Cardones, AR; Carlesimo, M; Caro, G; Freites-Martinez, A; Hirner, JP; Markova, A; McLellan, BN ...
Published in: Int J Dermatol
August 2023

BACKGROUND: Cutaneous immune-related adverse events (cirAEs) remain a prevalent and common sequelae of immune checkpoint inhibitor (ICI) therapy, often necessitating treatment interruption and prolonged immune suppression. Treatment algorithms are still poorly defined, based on single-institution case reports without adequate safety assessments, and subject to publication bias. METHODS: Data in this registry were collected through a standardized REDCap form distributed to dermatologists via email listserv. RESULTS: Ninety-seven cirAEs were reported from 13 institutions in this registry. Topical and systemic steroids were the most common treatments used; however, targeted treatment matched to disease morphology was identified at numerous sites. Novel cirAE therapy uses that to our knowledge have not been previously described were captured including tacrolimus for the treatment of follicular, bullous, and eczematous eruptions and phototherapy for eczematous eruptions. Moreover, further evidence of cirAE treatment applications sparsely described in literature were also captured in this study including dupilumab and rituximab for bullous eruptions, phototherapy for lichenoid and psoriasiform eruptions, and acitretin for psoriasiform eruptions, among others. No serious adverse events were reported. Numerous targeted therapeutics including dupilumab, rituximab, and psoriasis biologics, among others, were associated with a cirAE grade improvement of ≥2 grades in every patient treated. CONCLUSION: This study suggests that a multi-institutional registry of cirAEs and management is not only feasible but that the information collected can be used to detect, evaluate, and rigorously assess targeted treatments for cirAEs. Further expansion and modification to include treatment progression may allow for sufficient data for specific treatment recommendations to be made.

Duke Scholars

Published In

Int J Dermatol

DOI

EISSN

1365-4632

Publication Date

August 2023

Volume

62

Issue

8

Start / End Page

1020 / 1025

Location

England

Related Subject Headings

  • Tacrolimus
  • Skin
  • Rituximab
  • Psoriasis
  • Humans
  • Exanthema
  • Dermatology & Venereal Diseases
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mital, R., Otto, T. S., Savu, A., Baumrin, E., Cardones, A. R., Carlesimo, M., … Kaffenberger, B. H. (2023). Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management. Int J Dermatol, 62(8), 1020–1025. https://doi.org/10.1111/ijd.16714
Mital, Rohan, Tracey S. Otto, Andrei Savu, Emily Baumrin, Adela R. Cardones, Marta Carlesimo, Gemma Caro, et al. “Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.Int J Dermatol 62, no. 8 (August 2023): 1020–25. https://doi.org/10.1111/ijd.16714.
Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, et al. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management. Int J Dermatol. 2023 Aug;62(8):1020–5.
Mital, Rohan, et al. “Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.Int J Dermatol, vol. 62, no. 8, Aug. 2023, pp. 1020–25. Pubmed, doi:10.1111/ijd.16714.
Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, Caro G, Freites-Martinez A, Hirner JP, Markova A, McLellan BN, Rossi A, Sauder MB, Seminario-Vidal L, Sibaud V, Owen DH, Dulmage BO, Chen ST, Kaffenberger BH. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management. Int J Dermatol. 2023 Aug;62(8):1020–1025.
Journal cover image

Published In

Int J Dermatol

DOI

EISSN

1365-4632

Publication Date

August 2023

Volume

62

Issue

8

Start / End Page

1020 / 1025

Location

England

Related Subject Headings

  • Tacrolimus
  • Skin
  • Rituximab
  • Psoriasis
  • Humans
  • Exanthema
  • Dermatology & Venereal Diseases
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences